Multiple Sclerosis Journal - October 2017 - 1495

A Manouchehrinia, O Beiki et al.
Author contribution
A.M. designed the study, analysed and interpreted
data, and wrote and revised the manuscript. O.B. interpreted data and revised the manuscript. J.H. designed
the study, interpreted data and revised the manuscript.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: A.M. and O.B.
report no conflicts of interest. J.H. received honoraria
for serving on advisory boards for Biogen, SanofiGenzyme and Novartis and speaker's fees from
Biogen, Merck-Serono, Bayer-Schering, Teva and
Sanofi-Genzyme. He has served as PI for projects
sponsored by, or received unrestricted research support from, Biogen, Merck-Serono, TEVA, Novartis,
Sanofi-Genzyme and Bayer-Schering.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was funded by
Biogen. The funders had no role in study design, data
collection and analysis, decision to publish or preparation of the manuscript. Biogen courtesy reviewed
and provided feedback on the paper to the authors.
The authors had full editorial control of the paper and
provided their final approval of all content.

References
1. Confavreux C and Vukusic S. The clinical course
of multiple sclerosis. Handb Clin Neurol 2014; 122:
343-369.
2. Tremlett H, Zhao Y, Rieckmann P, et al. New
perspectives in the natural history of multiple
sclerosis. Neurology 2010; 74(24): 2004-2015.
3. Ahlgren C, Odén A and Lycke J. High nationwide
prevalence of multiple sclerosis in Sweden. Mult
Scler 2011; 17(8): 901-908.
4. Ahlgren C, Odén A and Lycke J. High nationwide
incidence of multiple sclerosis in Sweden. PLoS ONE
2014; 9(9): e108599.
5. Hillert J and Stawiarz L. The Swedish MS registry:
Clinical support tool and scientific resource. Acta
Neurol Scand 2015; 132(199): 11-19.
6. Andersen O. From the Gothenburg cohort to the
Swedish multiple sclerosis registry. Acta Neurol
Scand 2012; 195: 13-19.
7. Kurtzke JF. Rating neurologic impairment in multiple
sclerosis: An expanded disability status scale (EDSS).
Neurology 1983; 33(11): 1444-1452.

journals.sagepub.com/home/msj

8. Royston P and Lambert PC. Flexible parametric
survival analysis using Stata: Beyond the Cox model.
College Station, TX: Stata Press, 2011.
9. Tremlett H, Paty D and Devonshire V. Disability
progression in multiple sclerosis is slower than
previously reported. Neurology 2006; 66(2):
172-177.
10. Wooldridge JM. Inverse probability weighted
estimation for general missing data problems. J
Econometrics 2007; 141(2): 1281-1301.
11. Wooldridge JM. Econometric analysis of cross
section and panel data. Cambridge, MA: The MIT
Press, 2010.
12. StataCorp. Stata statistical software: Release 14.
College Station, TX: StataCorp LP, 2009.
13. Scalfari A, Neuhaus A, Degenhardt A, et al. The
natural history of multiple sclerosis: A geographically
based study 10: Relapses and long-term disability.
Brain 2010; 133(7): 1914-1929.
14. Confavreux C and Vukusic S. Age at disability
milestones in multiple sclerosis. Brain 2006; 129(Pt
3): 595-605.
15. Leray E, Yaouanq J, Le Page E, et al. Evidence for a
two-stage disability progression in multiple sclerosis.
Brain 2010; 133(7): 1900-1913.
16. Debouverie M, Pittion-Vouyovitch S, Louis S, et al.
Natural history of multiple sclerosis in a populationbased cohort. Eur J Neurol 2008; 15(9): 916-921.
17. Pittock SJ, Mayr WT, McClelland RL, et al.
Disability profile of MS did not change over 10 years
in a population-based prevalence cohort. Neurology
2004; 62(4): 601-606.
18. Vukusic S and Confavreux C. Prognostic factors for
progression of disability in the secondary progressive
phase of multiple sclerosis. J Neurol Sci 2003;
206(2): 135-137.
19. Runmarker B and Andersen O. Prognostic factors in
a multiple sclerosis incidence cohort with twentyfive years of follow-up. Brain 1993; 116(Pt 1):
117-134.
20. Myhr KM, Riise T, Vedeler C, et al. Disability and
prognosis in multiple sclerosis: Demographic and
clinical variables important for the ability to walk and
awarding of disability pension. Mult Scler 2001; 7(1):
59-65.
21. Koch M, Kingwell E, Rieckmann P, et al. The natural
history of secondary progressive multiple sclerosis. J
Neurol Neurosur Ps 2010; 81(9): 1039-1043.
22. Manouchehrinia A, Tanasescu R, Tench CR, et al.
Mortality in multiple sclerosis: Meta-analysis of
standardised mortality ratios. J Neurol Neurosur Ps
2016; 87: 324-331.

Visit SAGE journals online
journals.sagepub.com/
home/msj

SAGE journals

1495

http://journals.sagepub.com/home/msj http://journals.sagepub.com/home/msj https://journals.sagepub.com/home/msj

Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017